Ledger. Australian venture funding, tracked

President & CEO, Glyscend

Ashish Nimgaonkar

Coverage

Stories naming Ashish Nimgaonkar. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

News

Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment

Glyscend reports encouraging Phase 1 biomarker data for its diabetes drug GLY-200, announces US FDA clearance of its investigational new drug application, and has begun enrolling patients in a Phase 2 trial.

Brandon BioCatalyst portfolio 21 Sep 2022 Adelaide Medical SchoolGlyscendJohns Hopkins UniversityRoyal Adelaide HospitalUNC School of MedicineAshish NimgaonkarProfessor Christopher RaynerJohn Buse
Key hire

Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment

Biotech Glyscend reports its Phase 1 trial of GLY-200 for type 2 diabetes completed safely, and appoints Mark Fineman as Chief Development Officer ahead of a planned US regulatory filing and Phase 2 work.

Brandon BioCatalyst portfolio 12 May 2022 AmylinBiosplice TherapeuticsElcelyx TherapeuticsGlyscendJohns Hopkins UniversityTHRUST Strategic CommunicationsAshish NimgaonkarMark FinemanMonique Allaire

Something wrong? Tell us